TICAM1 Antikörper (AA 385-448)

Produktnummer ABIN7874539

Der Kaninchen Polyklonal anti-TICAM1 Antikörper (ABIN7874539) detektiert spezifisch TICAM1 in WB, ELISA und FACS. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für TICAM1 Antikörper (AA 385-448) (ABIN7874539)

Target: TICAM1 (Toll-Like Receptor Adaptor Molecule 1 (TICAM1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser TICAM1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Flow Cytometry (FACS)

Produktdetails anti-TICAM1 Antikörper

Bindungsspezifität: AA 385-448

Verwendungszweck: TICAM1 Antibody / TRIF

Aufreinigung: Antigen affinity purified

Immunogen: Recombinant human protein (amino acids S385-H448) was used as the immunogen for the TICAM1 antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the TICAM1 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: After reconstitution, the TICAM1 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Details zu TICAM1

Target: TICAM1 (Toll-Like Receptor Adaptor Molecule 1 (TICAM1))

Andere Bezeichnung: TICAM1

Hintergrund: TICAM1 (TIR DOMAIN-CONTAINING ADAPTOR MOLECULE 1), also known as TRIF, is an adapter in responding to activation of toll-like receptors (TLRs). It mediates the rather delayed cascade of two TLR-associated signaling cascades, where the other one is dependent upon a MyD88 adapter. By genomic sequence analysis, Oshiumi et al. (2003) mapped the TICAM1 gene to chromosome 19p13.3. By coimmunoprecipitation analysis, Oshiumi et al. (2003) showed that TICAM1 interacts specifically with TLR3, but not with other TLRs. Functional analysis showed that the association of TLR3 and TICAM1 mediates dsRNA activation of IFNB, through NFKB, AP1, or IRF3. TICAM1 activation of NFKB was found to occur predominantly through IRAK1 rather than IRAK2. Small interfering (si)RNA blockage of TICAM1, just upstream of the TIR domain, reduced IFNB production in response to dsRNA.

UniProt: Q8IUC6

Pathways: TLR Signalweg, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Hepatitis C, Toll-Like Receptors Cascades